Elixir Pharmaceuticals
One Kendall Square
Building 1000, Fifth Floor
Cambridge
Massachusetts
02139
United States
Tel: 617-995-7000
Fax: 617-995-7050
Website: http://www.elixirpharm.com/
Email: info@elixirpharm.com
28 articles with Elixir Pharmaceuticals
-
Elixir Pharmaceuticals Signs Option Agreement with a Major Pharmaceutical Company, Novartis Corporation; Deal Could Exceed $500 Million, Completes $12M Equity Financing
5/20/2009
-
Elixir Pharmaceuticals' Phase III Trial of Metformin-Mitiglinide Combination Therapy Demonstrates Significant Reductions in HbA1c (Blood Glucose) Levels Compared to Type 2 Diabetes Patients Not Well-Controlled on Metformin Alone
11/19/2008
-
Elixir Pharmaceuticals to Present at the UBS Warburg Global Life Sciences Conference
9/18/2008
-
Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University School of Medicine
7/1/2008
-
Elixir Pharmaceuticals Announces Ghrelin Agonist Data Presentation at the Endocrine Society Annual Meeting
6/18/2008
-
Elixir Pharmaceuticals Announces New Data at the 2008 American Diabetes Association Annual Meeting
6/9/2008
-
Elixir Pharmaceuticals Researchers Publish New Data Validating Ghrelin as a Key Metabolic Regulator
5/28/2008
-
Elixir Pharmaceuticals Announces Issuance of SIRT Patent Covering Development of New Therapies Based on Breakthrough Science
4/28/2008
-
Elixir Pharmaceuticals Establishes National Diabetes Advisory Board
4/9/2008
-
Elixir Pharmaceuticals Presents New Data on Ghrelin Inhibition at Keystone Meeting
2/22/2008
-
Elixir Pharmaceuticals to Present at Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/7/2008
-
Elixir Pharmaceuticals Sees IPO of 5 Million Shares at $14-$16 each
12/18/2007
-
Elixir Pharmaceuticals Names Paul M. Martha, M.D. as Chief Medical Officer
10/25/2007
-
Elixir Pharmaceuticals Plans $86.25 Million IPO
9/24/2007
-
Elixir Pharmaceuticals Initiates Final Phase III Clinical Study Prior to NDA
8/20/2007
-
Elixir Pharmaceuticals to Present Data from Programs to Treat and Prevent Metabolic Diseases
7/26/2007
-
Elixir Pharmaceuticals Announces Presentation of Data in Programs to Treat and Prevent Metabolic Diseases
7/17/2007
-
Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting
6/25/2007
-
Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast(R) to Maintain Glycemic Control in Patients with Type 2 Diabetes
6/25/2007
-
Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
6/5/2007